Home > Browse Research > Life Sciences > Pharmaceuticals > Vaccines > Cancer Vaccines

Cancer Vaccines: market research reports

Cancer Vaccines market research reports and industry analysis

Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines 10/14/2010 \| published by: BioSeeker Group AB ... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ... \| read more...	$4,830.00
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition 9/1/2010 \| published by: Kalorama Information ... of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even ... \| read more...	$1,500.00
Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry 8/1/2010 \| published by: Kalorama Information ... of insurance companies, retail outlets and the media. The global market for vaccines experienced strong growth through 2009 and this is expected to continue through the forecast period. Growth is being fueled by new product ... \| read more...	$3,995.00
Vaccines Review and Outlook 2010 8/1/2010 \| published by: PharmaLive Special Reports ... outpacing oncology. The recently renewed interest in the vaccine sector is attributed to advances in technology, federal liability protection for developers, increasing global demand, and premium pricing for new products. The impact of vaccines on ... \| read more...	$415.00
Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates 7/1/2010 \| published by: Business Insights ... in technical capabilities have allowed vaccines to move beyond pre-emptive (prophylactic) immunization and into treatment of established diseases. In April 2010, Dendreon’s Provenge became the first ever cancer vaccine to be approved by the US ... \| read more...	$3,835.00
Competitor Analysis: HPV Vaccines 5/1/2010 \| published by: La Merie Publishing ... cervical precancer as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database ... \| read more...	$194.00
Licensing Opportunities: Cancer Vaccines 3/16/2010 \| published by: Decision Resources ... cacy has been disappointing for many vaccines, however, and the development of these vaccines is a high-risk endeavor. This risk is balanced by the prospective benefi t of a new category of potential blockbusters that ... \| read more...	$4,600.00
Therapeutic Vaccines: The Global Market 3/1/2010 \| published by: BCC Research ... forecasts, with compound annual growth rates (CAGRs), through 2014 Focus on companies poised to introduce products during the forecast period and how these introductions will play out in terms of the competitive environment Explain how ... \| read more...	$5,450.00
Cancer Vaccines - Pipeline Analysis and Market Forecasts to 2016 1/15/2010 \| published by: GlobalData ... analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insight on the prevalent competitive landscape and the emerging players ... \| read more...	$2,000.00
The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis 12/31/2009 \| published by: GBI Research ... the global vaccines sales, volume and price forecasts to 2015. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global vaccines market. The report analyzes the markets for vaccines in ... \| read more...	$3,500.00
Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness 12/17/2009 \| published by: Datamonitor ... to conventional pharmacotherapy. First candidates have reached late-stage clinical development. Scope Strategic analysis of therapeutic vaccine pipelines and key clinical candidates across several disease areas outside cancer Thorough assessment of opportunities and challenges for therapeutic ... \| read more...	$3,800.00
Global Vaccines Market 12/7/2009 \| published by: Frost & Sullivan ... America, Europe, and Rest-of-World, with geographic and company market shares at the global level. Vaccines as a value of total revenues for key companies in the market are also assessed, Quarter-by-Quarter HPV vaccine growth rate ... \| read more...	$6,000.00
Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies 12/7/2009 \| published by: Datamonitor ... marketed therapeutic cancer vaccine in the seven major markets is now closer to reality. Scope Forecast sales of the therapeutic cancer vaccines in late-phase development in the seven major markets over the period 2009 to ... \| read more...	$11,400.00
China Vaccine Industry Report, 2008-2009 8/3/2009 \| published by: Research in China ... person-portions annually, besides, varieties and quantity also ranks the top in the world. Output of common vaccine reaches 500 million person-portions such as HBV vaccine, measles vaccine, etc. Fully planned immunization has been realized. Compared ... \| read more...	$1,500.00
Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry 6/1/2009 \| published by: Kalorama Information ... regions. This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent ... \| read more...	$3,995.00
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition 11/1/2008 \| published by: Kalorama Information ... vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many ... \| read more...	$3,995.00
Cancer Vaccine Developments to 2013 9/3/2007 \| published by: Espicom Healthcare Intelligence ... 2013. The launch of Sanofi Pasteur MSD's Gardasil and GSK’s Cervarix has propelled cancer vaccines from research obscurity to a key area of commercial and clinical interest. But can the sector capitalise on these gains ... \| read more...	$2,265.00
Building Better Cancer Vaccines: The Progress and Promise of R&D 7/30/2007 \| published by: Decision Resources ... radiation have improved the clinical outcomes of many patients, these treatments have limitations and toxicities that can deter their utility. Thus, there is substantial market opportunity for cancer vaccines. Get the Answers You Need to ... \| read more...	$4,600.00
The Emerging Cancer Vaccine Market, 2nd Edition 11/1/2006 \| published by: Kalorama Information ... trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. ... \| read more... Buy by the section \|	$1,200.00
Analytical Tool - Competitive Outlook on Cancer Vaccines 8/4/2006 \| published by: BioSeeker Group AB ... of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and ... \| read more...	$4,092.00
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology 8/3/2006 \| published by: BioSeeker Group AB ... of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide ... \| read more...	$5,003.00
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006 3/20/2006 \| published by: BioSeeker Group AB ... based vaccine drugs, therapeutic and preventive vaccines included. Vaccines are being developed for over 30 different cancer indications and the number of vaccine targets has increased to over 50 different molecular targets in just a ... \| read more...	$1,979.00
Pharmaceuticals and Politics: Will Political Opinion Affect the Future of HPV Vaccines? 12/19/2005 \| published by: Decision Resources ... not been well characterized, and the virus has a propensity to persist, produce recurrent clinical disease, and cause cancer. Merck's October 2005 announcement that its HPV vaccine, Gardasil, proved to be 100% effective in preventing ... \| read more...	$4,600.00
Outlook for Cancer Vaccine Development 5/23/2005 \| published by: Decision Resources ... viable therapeutic options. The first major launch of a cancer vaccine, designed to prevent human papillomavirus and therefore cervical cancer, is expected in 2006. In this report, we discuss the unmet needs in the cancer ... \| read more...	$4,600.00
Therapeutic Vaccines for Cancer: On the Threshold of Success 4/5/2005 \| published by: Drug and Market Development Publishing ... of therapeutics currently in development, as well as those that have been discontinued. Development strategies are also discussed in detail. Primary market research was utilized to elucidate the opinions of cancer vaccine developers, and responses ... \| read more...	$4,950.00

< prev 1 2 3 4 5 6 7 next >